Julie Eggington, MS, PhD’s Post

Going to AMP? Come hear about the upcoming version of variant classification guidelines we have been working on!

Come learn about the latest draft of the sequence variant classification guidelines!

🔎 Join our expert panel as they discuss the current and future perspectives for bispecific antibodies in #MultipleMyeloma. The symposium was led by Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. He was joined by guest speakers Naresh Bumma, Amrita Krishnan, and Sergio Giralt; together they explored BCMA-directed and alternative novel strategies using bispecific antibodies and the practical management of adverse events with immunotherapies. The speakers used example clinical cases to emphasize how their findings can be applied to real-world scenarios. A must watch! Don’t miss out! https://loom.ly/P-xfbwg https://loom.ly/inOoec8 https://loom.ly/KQW4lAU https://loom.ly/_VtODJ4 #bispecific #myeloma #mmsm European School of Haematology (ESH)

We are thrilled to share a recording of a GlycoNet webinar featuring Dr. Paula Videira, Co-Founder of CellmAbs, Co-director of GLYCOTwinning, and Associate Professor at Faculdade de Ciências e Tecnologia da Universidade NOVA de Lisboa. Introduced by Mr. David Firer, Chair of the GlycoNet Trainee Association – Executive Committee, Dr. Videira dives deep into "Unlocking the Glycoimmune Potential: Novel Strategies for Advanced Immunotherapy". Additionally, don’t miss the insightful presentation by her PhD student, Ms. Rita Adubeiro Lourenço, on "Deciphering the Enigmatic Role of O-glycan Signatures in Cancer". 👉 Watch the full recording here: https://lnkd.in/drFNUuS2 Learn more about GlycoNet and GLYCOTwinning and join us in advancing the field of glycomics and immunotherapy. #GlycoNet #GLYCOTwinning #Glycomics #glycobiology #CancerResearch #Glycoscience #Webinar

Watch Sagar Lonial’s presentation from our latest symposium on the current and future perspectives for bispecific antibodies in #MultipleMyeloma. Key points covered in this presentation include: ▪️ The increasing options for patients with relapsed/refractory multiple myeloma ▪️ The mechanism of action of BsAbs works by binding to CD3 and a plasma cell target ▪️ BsAbs bring T-cells in close proximity to malignant tumor cells, resulting in #myeloma cell death ▪️ Rational targets include BCMA, GPRC5D, and FcRH5 https://loom.ly/P-xfbwg #mmsm

Try AgeLOC Cordyceps https://lnkd.in/g3h2DBW (Not ADD Pitch-FYI) https://lnkd.in/dXi5ZFWq 6 Benefits of Cordyceps, All Backed by Science

"Non-invasive tests may actually hold more predictive value than imaging tests, which makes sense because they can detect disease at a much lower level...perhaps this is an opportunity to improve the way we define remission." Mark Roschewski discusses the findings and implications from his recent study presented at #ash23 that compared the performance of PhasED-Seq ctDNA vs. PET/CT scans for response assessment after frontline therapy for aggressive #DLBCL. These findings require us to rethink how we best measure response in lymphoma - and this is particularly critical for clinical trials. When used in conjunction with standard PET/CT imaging, PhasED-Seq's ultra-sensitive ctDNA platform may be a more accurate measure of response, and thereby, a more confident indicator of therapeutic efficacy for drug development and approvals. Watch the full video here: https://lnkd.in/dqJvbfw9 #mrd #ctdna #lymphoma #clinicaltrials

Check out my interview with "The Onc Doc": Sanjay Juneja, M.D. on his podcast "Target Cancer." We discuss how the SAGE Oncotest can guide you and your oncologist to identify the best treatment for your very unique cancer.

Vivli Researcher Spotlight: 🔦 Check out our newest update, with researcher Dr. Ashley Hopkins on using Vivli to access #individualpatientdata and making an impact in #cancertreatment: 👉 https://lnkd.in/gPNFVpRi

Many thanks to all involved in this work. The central observation of a PGF2a induced phenotype change is a fascinating one. Raises questions of whether this is unique to PGF2a or also applies to other agonists of human labour such as oxytocin or PGE2. We also need to understand the relationship of these changes to the effects of progesterone.